Patents by Inventor Daniel Strimling

Daniel Strimling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250043296
    Abstract: The invention provides methods of using chloroplast-selectable markers to detect nuclear genome editing. The methods involve selecting a genetic modification that has occurred in a nuclear genome of a photosynthetic cell; transforming a photosynthetic cell with a ribonucleoprotein complex that effects a genetic modification in the genome in the nucleus of a photosynthetic cell; transforming the photosynthetic cell with a construct that effects an insertion of a selectable marker into the plastome of a plastid of the cell; selecting for photosynthetic cells having the selectable marker inserted into the plastome; and thereby selecting for the genetic modification to the genome in the nucleus of the photosynthetic cell.
    Type: Application
    Filed: August 2, 2024
    Publication date: February 6, 2025
    Inventors: John Verruto, Daniel Strimling
  • Patent number: 11746321
    Abstract: The invention provides engineered Vibrio sp. organisms that comprise a genetic modification to either or both of the lpxL and/or lpxM genes. The organisms score substantially lower in an in vitro endotoxin assay versus the unmodified or wild type organism. The organisms preserve substantially the growth rate of the corresponding unmodified organisms. The organisms can also have an exogenous nucleic acid cloned in the organism, or an exogenous nucleic acid encoding a protein, polypeptide, or peptide expressed by the organism, and optionally secreted from the organism.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: September 5, 2023
    Assignee: Telesis Bio Inc.
    Inventors: Matthew T Weinstock, Daniel G. Gibson, Daniel Strimling
  • Publication number: 20210284954
    Abstract: The invention provides engineered Vibrio sp. organisms that comprise a genetic modification to either or both of the lpxL and/or lpxM genes. The organisms score substantially lower in an in vitro endotoxin assay versus the unmodified or wild type organism. The organisms preserve substantially the growth rate of the corresponding unmodified organisms. The organisms can also have an exogenous nucleic acid cloned in the organism, or an exogenous nucleic acid encoding a protein, polypeptide, or peptide expressed by the organism, and optionally secreted from the organism.
    Type: Application
    Filed: March 25, 2021
    Publication date: September 16, 2021
    Inventors: Matthew T Weinstock, Daniel G. Gibson, Daniel Strimling
  • Patent number: 10968496
    Abstract: The invention provides engineered Vibrio sp. organisms that comprise a genetic modification to either or both of the lpxL and/or lpxM genes. The organisms score substantially lower in an in vitro endotoxin assay versus the unmodified or wild type organism. The organisms preserve substantially the growth rate of the corresponding unmodified organisms. The organisms can also have an exogenous nucleic acid cloned in the organism, or an exogenous nucleic acid encoding a protein, polypeptide, or peptide expressed by the organism, and optionally secreted from the organism.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: April 6, 2021
    Assignee: Codex DNA, Inc.
    Inventors: Matthew T Weinstock, Daniel G. Gibson, Daniel Strimling
  • Publication number: 20190153554
    Abstract: The invention provides engineered Vibrio sp. organisms that comprise a genetic modification to either or both of the lpxL and/or lpxM genes. The organisms score substantially lower in an in vitro endotoxin assay versus the unmodified or wild type organism. The organisms preserve substantially the growth rate of the corresponding unmodified organisms. The organisms can also have an exogenous nucleic acid cloned in the organism, or an exogenous nucleic acid encoding a protein, polypeptide, or peptide expressed by the organism, and optionally secreted from the organism.
    Type: Application
    Filed: October 8, 2018
    Publication date: May 23, 2019
    Inventors: Matthew T Weinstock, Daniel G. Gibson, Daniel Strimling